A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

Launched by SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Jul 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called SSGJ-707 for patients with advanced or recurrent endometrial cancer and ovarian cancer that has not responded to standard chemotherapy. The main goal of the study is to see if SSGJ-707, when combined with chemotherapy, is safe and effective for these patients. The trial is taking place at multiple locations, and it is currently looking for participants.

To be eligible for the study, participants should be between 18 and 75 years old, have advanced endometrial cancer or platinum-resistant ovarian cancer, and have a good performance status, meaning they can carry out daily activities with minimal assistance. Participants should expect to undergo treatment and regular check-ups to monitor their health and how well the treatment is working. It's important to note that individuals with certain health issues, such as uncontrolled brain disease or severe reactions to past cancer treatments, may not qualify. If you're interested in learning more about whether you or a loved one might be eligible, discussing this trial with a healthcare provider could be a good next step.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age:18-75 years old
• • 2. Advanced endometrial cancer and platinum-resistant ovarian cancer
• • 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• • 4. Expected survival \>=12 weeks.
• • 5. Signed informed consent form.
• Exclusion Criteria:
• • 1. Known uncontrolled or symptomatic central nervous system metastatic disease.
• • 2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0).
• • 3. Inadequate organ or bone marrow function.
• • 4. Pregnant or breast-feeding woman.
• • 5. Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.